Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Aug;271(8):5122-5136.
doi: 10.1007/s00415-024-12433-x. Epub 2024 May 31.

Electroacupuncture and carbamazepine for patients with trigeminal neuralgia: a randomized, controlled, 2 × 2 factorial trial

Affiliations
Randomized Controlled Trial

Electroacupuncture and carbamazepine for patients with trigeminal neuralgia: a randomized, controlled, 2 × 2 factorial trial

Rongrong Li et al. J Neurol. 2024 Aug.

Abstract

Background: Trigeminal neuralgia (TN) is difficult to treat due to its severe pain intensity and recurring episodes, which significantly impact quality of life.

Objectives: We aimed to assess the effectiveness of electroacupuncture (EA) in alleviating the pain intensity in TN, and to determine whether EA combined with low-dosage carbamazepine (CBZ) has a synergistic effect.

Methods: A multi-centre, randomized, 2 × 2 factorial trial was conducted. Participants who met the inclusion criteria received active EA or sham EA for 60 min, three times a week for four weeks; CBZ (300 mg per day) or placebo for four weeks. The primary outcome was the change in visual analog scale (VAS) score from baseline to weeks 2, 4, 16, and 28. Secondary outcomes included quality of life and adverse events.

Results: A total of 120 participants (75 females and 45 males; mean (SD) age, 58.5 (15.3) years) were included. The main effects of EA and CBZ were significant (P < 0.001), and there was a significant interaction was identified between the interventions (P = 0.041). Participants who received EA (mean difference [MD], -0.3 [95% CI, -0.40 to -0.20] at week 2; -1.6 [-1.70 to -1.50] at week 4; -1.1 [-1.31 to -0.89] at week 16; -0.8 [-1.01 to -0.59] at week 28), CBZ (MD, -0.6 [95% CI, -0.70 to -0.50] at week 2; -0.9 [-1.03 to -0.77] at week 4, -0.2 [-0.41 to 0.01] at week 16, 0.2 [-0.01 to 0.41] at week 28), and the combination of both (MD, -1.8 [95% CI, -1.90 to -1.70] at week 2; -3.7 [-3.83 to -3.57] at week 4, -3.4 [-3.61 to -3.19] at week 16, -2.9 [-3.11 to -2.69] at week 28) had a greater reduction in VAS score over the treatment phase than their respective control groups (sham EA, placebo, and sham EA plus placebo). EA-related adverse events (6/59, 10.17%) were lower than that of CBZ (15/59, 25.42%) during the whole phases.

Conclusions: EA or CBZ alone are effective treatments for TN, while the combination of EA and low-dosage CBZ exerts a greater benefit. These findings in this trial demonstrate that the combination of EA and low-dosage CBZ may be clinically effective under certain circumstances.

Trial registration: NCT03580317.

Keywords: Carbarmazepine; Electroacupuncture; Factorial design; Randomized controlled trial; Trigeminal neuralgia.

PubMed Disclaimer

Conflict of interest statement

All other authors declare that they have no competing interest.

Figures

Fig. 1
Fig. 1
Modified CONSORT flow diagram for the trial. Abbreviations: VAS = visual analogue scale; EA = electroacupuncture; CBZ = carbamazepine; SEA = sham electroacupuncture; P = placebo; SF-MPQ = Short-Form McGill pain questionnaire; PRI: pain rating index; PPI: present pain intensity; BPI-Facial: brief pain inventory-facial scale; PGIC: patient global impression of change

References

    1. Cruccu G (2017) Trigeminal neuralgia. Continuum (Minneap Minn). 23(2, Selected Topics in Outpatient Neurology):396–420 - PubMed
    1. Treede RD, Rief W, Barke A et al (2019) Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain 160(1):19–27 10.1097/j.pain.0000000000001384 - DOI - PubMed
    1. Maarbjerg S, Gozalov A, Olesen J et al (2014) Concomitant persistent pain in classical trigeminal neuralgia–evidence for different subtypes. Headache 54(7):1173–1183 10.1111/head.12384 - DOI - PubMed
    1. Latorre G, González-García N, García-Ull J et al (2023) Diagnosis and treatment of trigeminal neuralgia: consensus statement from the Spanish Society of Neurology’s Headache Study Group. Neurologia (Engl Ed) - PubMed
    1. Zakrzewska JM, Wu J, Mon-Williams M et al (2017) Evaluating the impact of trigeminal neuralgia. Pain 158(6):1166–1174 10.1097/j.pain.0000000000000853 - DOI - PubMed

Publication types

Associated data